Introduction
Ischemic events usually occur in patients who undergo percutaneous coronary intervention (PCI). Whether those events occur mainly depends on the activation of platelets and the generation of thrombin, and both processes are mediated by a variety of agonists (1, 2) . Dual antiplatelet treatment with clopidogrel and aspirin to suppress platelet reactivity (PR) has proven to be an efficacious therapy and can be used to prevent ischemic events in patients with coronary heart disease (CHD) after PCI (1, 3, 4) . Thromboelastography (TEG) has been performed in order to monitor and alleviate ischemic events, and TEG platelet mapping can adeptly assess the response of circulating platelets to both aspirin and clopidogrel in whole blood, as a previous study by the current authors indicated (5) . A TEG analysis can provide a large amount of information on the overall likelihood of thrombosis and the reaction to antiplatelet therapy. In TEG, an oscillating cup and a rotating pin suspended in a blood sample are connected by blood clots. Blood clot strength is measured using the proportional amplitude of the rotating pin. The maximum amplitude (MA) is the maximum clot strength, which defined as the parameter MA (2, 6) . Thus far, TEG is the only point-of-care testing (POCT) of platelet function that has been approved by China's Food and Drug Administration (FDA). However, the relationship between TEG and ischemic events in patients undergoing PCI has yet to be determined.
A previous study by the current authors indicated a definite relationship between gender and clopidogrel
Summary
Ischemic events after percutaneous coronary intervention (PCI) remain a major concern for patients with coronary heart disease (CHD). 
Materials and Methods

Patients
Seven hundred and fifty-nine consecutive patients who underwent elective PCI from January 2014 to February 2015were enrolled in a prospective observational study. All patients over the age of 18 had been administered aspirin in a dosage of 100 mg/day for at least 7 days. Exclusion criteria included a history of bleeding, an acute myocardial infarct (AMI) up to 48 h before enrolment, and use of glycoprotein (GP) IIb/IIIa inhibitors prior to the procedure. All of the patients were pre-treated with aspirin and a 600-mg dose of clopidogrel more than 12 h prior to the procedure, followed by a maintenance dose of aspirin 100 mg/ day and clopidogrel 75 mg/day for 2 y. This study was approved by the Institutional Review Board of Shanghai Chest Hospital (7563893).
Blood sampling and measurement of platelet-fibrin clot strength
Blood samples were obtained 18 to 24 hours after PCI. After the procedure, blood was drawn by venipuncture into vacutainer tubes (Becton-Dickinson, NJ, USA) with 3.8% trisodium citrate and USP lithium heparin (for TEG assay). The vacutainer blood tube was filled with blood and gently inverted three to five times in order to ensure that the sample was completely mixed with the anticoagulant. Platelet-fibrin clot strength was measured with the TEG Hemostasis System (Haemoscope Corporation, IL, USA) according to the manufacturer's instructions. Quantitative and qualitative values for the physical properties of clots were obtained with the automated analytical software TEG Hemostasis Analyzer (Haemoscope Corporation, IL, USA) according to the manufacturer's instructions.
Heparinized blood (360 μL) was rapidly added dropwise to a heparinase-coated cup and analyzed with TEG to detect the maximum amplitude of thrombininduced clot strength (MA Thrombin ). The mixed blood (340 μL) was added dropwise to a noncoated cup containing activator F and reptilase to generate a blood cross-linked clot without thrombin generation or platelet stimulation (MA Fibrin ). The last sample (340 μL) of heparinized blood was added dropwise to a nonheparinase-coated cup containing activator F and adenosine diphosphate-induced platelet-fibrin (ADP) or arachidonic acid (AA) to induce a blood-crosslinked clot with platelet activation (MA ADP or MA AA ).
Definitions and clinical follow-up
Platelet aggregation induced by ADP was defined as %Aggregation = [(MA ADP -MA Fibrin )/(MA Thrombin -MA Fibrin )] × 100%, and this value was calculated with software. The cut-off point for high on-treatment platelet reactivity (HPR) was expressed as ≥ 70% ADP-induced platelet aggregation with 2 μmol of ADP as measured with TEG (6).
Patients were followed for 24 months during hospitalization depending on the occurrence of adverse events. Patients that complied with antiplatelet medication were contacted by phone or by the clinic and an appointment was made for the postoperative follow-up. Endpoints included stent thrombosis, cardiac death, ischemic stroke, unplanned revascularization, and myocardial infarction. Stent thrombosis was determined using the definition of the Academic Research Consortium (7) . Cardiac death included a death due to any cardiovascular cause. Myocardial ischemia correlated with the overexpression of troponin I was regarded as myocardial infarction (8).
Statistical analysis
Statistical analysis was performed with SPSS version 21.0 (SPSS, Inc., IL, USA). Categorical variables were expressed as n (%) and continuous variables were expressed as the mean ± standard deviation (SD). The chi-square test and Student's t-test were respectively used to compare categorical variables and continuous variables among groups. Receiver operating characteristic (ROC) curve analysis was performed to determine the diagnostic accuracy of MA ADP in relation to ischemic events. Demographic and procedural variables were included in a multivariate Cox proportional hazards model to identify prognostic factors. P < 0.05 was regarded as statistically significant.
Results
Patients and demographic characteristics
Seven hundred and fifty-nine patients who underwent non-emergent PCI were enrolled and administered aspirin and clopidogrel therapy. One hundred and eighty-two of these patients were diagnosed with unstable angina and the remainder were diagnosed with stable angina. The baseline characteristics of patients are shown in Table 1 . The average age was (66.0 ± 9.6) years old and 72% of the patients were men. Fiftyeight patients (7.6%) experienced an ischemic event in the 2 years after elective PCI. In short, patients who was not correlated with ischemic events (P > 0.05) (81.1 ± 32.4% in the ischemic group vs. 71.4 ± 28.5% in the non-ischemic group). However, patients who experienced ischemic events had significantly greater ADP-induced platelet-fibrin clot strength (MA ADP ) than did patients who did not experience ischemic events (40.8 ± 10.1 mm vs. 26.7 ± 13.7 mm, P < 0.05). ROC analysis, which assessed the association between MA ADP and ischemic events, indicated that MA ADP had good predictive significance, resulting in an area under the curve (AUC) of 0.79 (95% CI: 0.72-0.87, P < 0.05, Figure 1A ). experienced an ischemic evens were more often female (43% vs. 27%, P < 0.05) and had a higher level of fasting blood glucose (FBG) compared to patients in the non-ischemic group ((8.7 ± 3.4) mmol/L vs. (6.8 ± 2.9) mmol/L, P < 0.05).
Association between platelet aggregation and ischemic events
Blood samples of all 759 patients were analyzed with the TEG system. The prevalence of HPR was 36% according to TEG (n = 273). As shown in Table 2 , posttreatment platelet AA-induced aggregation according to TEG did not differ markedly between the two groups (P > 0.05) (88.8 ± 41.9% in the ischemic group vs. 81.0 ± 23.1% in the non-ischemic group). Post-treatment platelet ADP-induced aggregation according to TEG 76 (10) 539 (71) 197 (26) 30 (4) 175 (23) 99 (13) 577 (76) 182 (24) 88.1 ± 39.7 193.5 ± 67.5 6.9 ± 2.9 4.2 ± 12. 4 (7) 48 (82) 21 (36) 4 (7) 16 (27) 16 (27) 51 (88) 7 (12) 80. 72 (10) 491 (70) 176 (25) 26 (4) 149 (21) 83 (12) 526 (75) 175 (25) 88.4 ± 39.7 193.1 ± 67. 6 6.8 ± 2.9 3.7 ± 11. Quartile analysis of the MA ADP consistently indicated that the incidence of ischemic events increased with higher quartiles ( Figure 1B) . Sixty-one percent of patients in the third quartile (an MA ADP of 34-44 mm) experienced ischemic events and 67% of patients in the fourth quartile (an MA ADP > 44mm) experienced ischemic events. Independent predictors of long-term ischemic events were assessed with a multivariate Cox proportional hazards model. MA ADP , being female, and FBG were independently and dramatically related to ischemic events, with a respective risk ratio of 8.9 (95% CI: 4.2-18.3), 5.3 (95% CI: 2.7-11.1), and 2.2 (95% CI: 1.1-3.9) (P < 0.05, Table 3 ).
Discussion
Patients undergoing PCI usually suffer from ischemic events, and the standard therapy for these patients has been the combined use of aspirin and clopidogrel (4) . The PREPARE-POST-STENTING study first indicated a relationship between MA ADP and the occurrence of ischemic events in 2005 (2) . Light transmittance aggregometry was used to determine platelet reactivity. Several studies have used TEG to predict platelet reactivity and ischemic events after PCI (2,9). The current study hypothesized that the MA ADP according to TEG would provide supererogatory information for post-stenting risk assessment. Results indicated that an MA ADP greater than 34 mm according to TEG suggested a higher risk of ischemic events. However, Gurbel et al. reported that an MA ADP greater than 47 mm according to TEG significantly predicted long-term ischemic events in contrast to other measurements (9) . Race is known to be an independent predictor of survival of coronary disease and individual differences in platelet reactivity are known to be heritable; several studies have found a lower frequency of epistaxis in Asians and African Americans than Caucasians (10, 11) .
Multifactorial processes such as clinical, demographic, and hemostatic components influence ischemic events, and especially those after PCI (12) . The current results suggested that only gender and the level of FBG differed significantly between ischemic and non-ischemic groups. Interestingly, the current results based on a Cox model indicated that female patients had a much higher risk of experiencing ischemic events than did male patients, and a previous study yielded a similar finding. Several studies have indicated that HPR is more prevalent in females than males because of a stronger platelet aggregation reaction to platelet agonist stimulation (13) (14) (15) . This might be caused by a high of clotting at the baseline, the effects of female hormone, or a diminished reaction to clopidogrel in female patients.
MA parameters according to TEG can detect the maximum amplitude of platelet aggregation and fibrinplatelet binding by GP IIb/IIIa (9). Circulating platelets are variably inhibited by platelet inhibitors. The MA ADP indicated the level of platelet reactivity induced by ADP. According to the current results, MA ADP may accurately predict the long-term ischemic events after PCI based on platelet inhibition by ADP. However, there has been reluctance to monitor antiplatelet therapy over the long term. There are several reasons for this reluctance, such as the introduction of artifacts due to laboratory methods, incomplete reflection of the actual thrombotic process in vivo, and failure to unequivocally establish a causal relationship between test results and the occurrence of thrombotic events. Over the past few years, knowledge of platelet receptor physiology has improved significantly and more patient-friendly assays of platelet function have been introduced. However, a large-scale prospective trial has yet to yield definitive evidence indicating that improved antiplatelet therapy based on a platelet function test actually helps patients. At present, TEG is a preferable technique to identify patients at risk of experiencing ischemic events, but the effectiveness of this technique needs to be assessed further in large-scale trials in the future. Thrombotic events occurred at a relatively low rate in previous prospective trials, and larger samples are needed to assess the potential for TEG to provide personalized treatment for patients with CHD (16) .
That said, the current study had several limitations. First, this subject was a prospective study that was not randomized, and findings still need to be verified in larger randomized clinical trials. Second, the clopidogrel loading dose used in this study may result in different levels of antiplatelet action in different patients.
In summary, the quantitative measurement of MA ADP with TEG allows more individualized antiplatelet treatment to prevent ischemic events, and this approach may help to improve predictive accuracy and facilitate personalized antiplatelet treatment.
